It is known that gain of functional mutations in K-ras occur at early stages in human pancreatic cancer patients or mouse models that were generated by knockout of tumor suppressor genes of p16, Arf, or p53, respectively or in combinations [12]–[14]. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.